Palivizumab biosimilar(Kidswell Bio)

N/A

Report date: 2025/03/07 17:34:38

Base Information

Drug NamePalivizumab biosimilar(Kidswell Bio)
Drug Alias NameGBS-008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionViral fusion proteins inhibitors
TargetsViral fusion proteins
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGene Techno Science
China Registration ClassN/A

Develop Information

Active CompaniesGene Techno Science
Inactive CompaniesN/A
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A